|
|
|
|
EuropaBio's 20 year anniversary: weekly spotlight on our members
 Novozymes is based on bioinnovation. This means that we apply industrial biotechnology to challenge and complement traditional thinking and applications. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. Together with customers, partners and the global community, we advance industrial performance, while preserving the planet’s resources and creating better lives. By applying Novozymes’ biological solutions, customers reduced their CO2 emissions by an estimated 60 million tons in 2015 - equivalent to taking 25 million cars off the road. Read more
|
|
|
Clear maladministration by the Commission when it comes to GMOs?
Decisions or lack thereof in the authorisation for GM food and feed are decisive to the competitiveness of a key part of the agri-food chain, the largest employer in Europe today. Economically speaking, the EU Commission estimated that the cost of disruptions in GMO trade could amount to € 9.6 billion per year. Furthermore, approving safe new products within legally prescribed and predictable timelines is the most obvious and linear generator of innovation, jobs and growth. What is needed now is political leadership that stands up for its own approval system and helps inform the public. Read more
Bringing biotech to you
By continuously pushing the boundaries of knowledge, biotechnology challenges us to discuss where and how to apply the innovative solutions it provides for the benefit of mankind. These discussions should not take place only in ivory towers or in high-level policy meetings: biotech enthusiasts need to engage at all levels of society to familiarise more people with biotech products and benefits. At least this is the thinking behind the European Biotech Week initiative, now in its fourth year and scheduled to take place from 26 September to 2 October 2016. Get involved
|
|
|
Healthcare biotech
The European Commission published a report on "enhanced cross-country coordination in the area of pharmaceutical product pricing". The study aims to analyse the policy options of external price referencing and differential pricing in terms of technical, economic and legal considerations, in order to investigate possible benefits from improved cross-country policy coordination in the area of pharmaceutical pricing. |
|
|
Industrial biotech
The forest industries and agriculture have a vital role to play in the future bioeconomy, as they can provide solutions to most of the current major challenges. The development of value chains for the advanced products based on resources from these sectors "requires a multidisciplinary approach and close collaboration". Discover more in these roadmaps
|
|
|
Agricultural biotech
Just like other crops, trees can also be genetically modified in order to introduce new, useful characteristics. Although such trees offer many socio-economic and environmental benefits, complex and unpredictable EU procedures are hindering their introduction to the market. This is the conclusion reached by researchers that call for a more scientifically substantiated decision process. Read more |
|
|
|
|
|
|
|
